Register for CytoCore among Industry Leaders in Cervical Cancer
Treatment Featured in Executive Healthcare Management
CEO Dr. Floyd Taub Highlights Latest Innovations and Practices in Upcoming Issue
CHICAGO – September 06, 2007– CytoCore Inc. (OTCBB:CYCR), the
biopharmaceutical research and medical device company for early detection and
treatment of reproductive-tract cancers, today announced that the quarterly
magazine Executive Healthcare Management will profile CytoCore in its upcoming
Q4 2007 issue. The publication is the industry's leading source for healthcare
professionals and physicians for evaluating and achieving their business goals.
CytoCore will be featured in this issue’s focused report on the detection and
treatment of cervical cancer. Also profiled are Cytyc, Dako, Genentech and
Genzyme, leading companies in the field of cancer detection and treatment. Floyd
Taub, M.D., CytoCore’s CEO, was chosen to write a thought-leader piece on the
topic, which will appear in the issue. Other contributors include Dr. Julie
Gerberding, director of the Centers for Disease Control and Prevention (CDC);
Dr. Denise Cardo, director of Healthcare and Quality Programs, CDC; Dr. Mark
Sobel, former head pathologist of the National Cancer Institute; and Dr. Elias
Zerhourni, director of the National Institute of Health.
“CytoCore is proud of its recognition by Executive Healthcare Management as one
of the leading companies addressing the prevention, detection and treatment of
cervical cancer,” said Dr. Floyd Taub, CEO of CytoCore. “Many exciting advances
have recently occurred in the field, and I’m pleased for the opportunity to
share my thoughts on the subject and shed light on new, innovative diagnostic
and therapeutic technologies that are redefining a major area of women’s
health.”
The Q4 2007 issue of Executive Healthcare Management featuring CytoCore will
appear in early October. The publication with web site and print distribution
reaches approximately 75,000 readers and can be viewed online at
http://www.executivehm.com
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized
in a laboratory or at the point-of-care, to assist in the early detection of
cervical, endometrial, and other cancers. The InPath(TM) System is being
developed to provide medical practitioners with highly accurate, low-cost,
cervical and uterine cancer screening systems that can be seamlessly integrated
into existing medical models. More information is available at:
www.CytoCoreInc.com
Certain statements in this release are forward-looking. These statements are
based on CytoCore's current expectations and involve many risks and
uncertainties, such as the company's inability to obtain sufficient financing,
the possibility that clinical trials will not substantiate CytoCore's
expectations with respect to the InPath(TM) System, and other factors set forth
in reports and documents filed by CytoCore with the Securities and Exchange
Commission. Actual results may differ materially from CytoCore's current
expectation depending upon a number of factors affecting the Company's business.
These factors include, among others, risks and uncertainties detailed in the
Company's periodic public filings with the Securities and Exchange Commission,
including but not limited to the Company's Annual Report on Form 10-K for the
year ended December 31, 2006. Except as expressly required by law, CytoCore
undertakes no obligation to publicly update or revise any forward-looking
statements contained herein.
Contact:
on behalf of CytoCore, Inc.
Gene Martineau, +1-212-348-1880
Communications & Business Development Consultant
ebm@interport.net
or
SIPR for CytoCore
Judy Curtis, +1-650-274-1509
judy@sipr.com
